ROCK1P1: A Promising Drug Target and Biomarker for the Treatment of Neurodegenerative Diseases

Target Name: ROCK1P1

NCBI ID: G727758

ROCK1P1

Other Name(s): Rho associated coiled-coil containing protein kinase 1 pseudogene 1 | Rho associated coiled-coil containing protein kinase 1 pseudogene 1, transcript variant 3 | ROCK1P1 variant 3 | ROCK1P

ROCK1P1: A Promising Drug Target and Biomarker for the Treatment of Neurodegenerative Diseases

Rocky River kinase 1 (ROCK1P1) is a protein that plays a critical role in the regulation of cell proliferation, differentiation, and survival. ROCK1P1 is a member of the Rho family of GTPases, which are known for their ability to regulate protein tyrosination and inactivation. ROCK1P1 has been implicated in the development and progression of various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and colorectal cancer. As a result, targeting ROCK1P1 has become an attractive research focus in the field of neuroscience and therapeutic development.

Diseased Implications of ROCK1P1 Malfunction

ROCK1P1 is a key regulator of the neurotransmitterInsulin-like growth factor (IGF) signaling pathway, which plays a crucial role in the development and maintenance of neural stem cells and their differentiated cell types. ROCK1P1 has been shown to regulate the phosphorylation and inactivation of several key components of the IGF signaling pathway, including tyrosine phosphorylation and inhibition of the protein-protein interaction between the cytoplasmic domain of ROCK1P1 and the alpha-tubulin protein. These changes in ROCK1P1 function have been implicated in the pathophysiology of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and colorectal cancer.

In Alzheimer's disease, ROCK1P1 has been shown to contribute to the misfolding and aggregation of beta-amyloid peptides, which are thought to play a key role in the development of neurofibrillary tangles and neuroplasmins in this disease. Similarly, in Parkinson's disease, ROCK1P1 has been implicated in the misfolding and aggregation of alpha-synuclein peptides, which are also thought to contribute to the development of neurofibrillary tangles in this disease.

Targeting ROCK1P1 for Therapeutic Intervention

The potential therapeutic intervention for ROCK1P1-related neurodegenerative diseases is the use of drugs that target ROCK1P1 and modulate its function. One approach to targeting ROCK1P1 is the use of small molecules that can inhibit the activity of ROCK1P1. One such compound is called ROCK1P1 inhibitor (RIP), which is a small molecule that binds to ROCK1P1 with high affinity and inhibits its GTPase activity.

In preclinical studies, RIP has been shown to be effective in animal models of Alzheimer's disease and Parkinson's disease, with potential therapeutic benefits. For example, treatment with RIP has been shown to improve cognitive function, reduce neurofibrillary tangles and astrocytes, and improve dopamine receptor function in both animal models of Alzheimer's disease.

Another approach to targeting ROCK1P1 is the use of antibodies that specifically target ROCK1P1 and can modulate its function. One such approach is the use of monoclonal antibodies (MAbs), which are laboratory-produced antibodies that are highly specific for a particular target protein. MAbs have been shown to be effective in targeting ROCK1P1 and modulating its function in preclinical studies.

While MAbs have shown promise in targeting ROCK1P1, there are concerns about their safety and potential adverse effects. To address these concerns, researchers have developed a new generation of antibodies that are designed to be more stable and less likely to cause adverse effects. One such approach is the use of affinity purification (AP) antibodies, which are antibodies that are produced by a cell-based assay and have a high affinity for

Protein Name: Rho Associated Coiled-coil Containing Protein Kinase 1 Pseudogene 1

The "ROCK1P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ROCK1P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets